Biologic therapy and tuberculosis: our experience and review of literature

Caterina Fabroni,1 Angelo Massimiliano D’Erme,2 Torello Lotti3 1Department of Dermatology, Misericordia e Dolce Hospital, Prato, Italy; 2Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy; 3Guglielmo Marconi University, Rome,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fabroni C, D&#39;Erme AM, Lotti T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/2f4cd91aaf0b4c7fbfe63d56d3212fb3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2f4cd91aaf0b4c7fbfe63d56d3212fb3
record_format	dspace
spelling	oai:doaj.org-article:2f4cd91aaf0b4c7fbfe63d56d3212fb32021-12-02T05:04:06ZBiologic therapy and tuberculosis: our experience and review of literature2230-326Xhttps://doaj.org/article/2f4cd91aaf0b4c7fbfe63d56d3212fb32013-07-01T00:00:00Zhttp://www.dovepress.com/biologic-therapy-and-tuberculosis-our-experience-and-review-of-literat-a13552https://doaj.org/toc/2230-326XCaterina Fabroni,1 Angelo Massimiliano D’Erme,2 Torello Lotti3 1Department of Dermatology, Misericordia e Dolce Hospital, Prato, Italy; 2Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy; 3Guglielmo Marconi University, Rome, Italy Abstract: Psoriasis is an inflammatory dermatologic disease that can often involve not only the skin and mucosal surfaces but also the bones and joints. It affects approximately 3% of the world’s population, and has a chronic-relapsing course. The management of psoriasis is often difficult and, particularly in the case of moderate to severe forms, the use of systemic therapies is mandatory. The introduction of biologic drugs has greatly improved our ability to treat psoriasis. However, it is necessary to underline that antitumor necrosis factor-α treatments may reactivate latent tuberculosis infection and cause particularly disseminated or extrapulmonary disease. Physicians should carry out proper screening of patients before starting treatment with antitumor necrosis factor-α, in order to identify individuals with latent tuberculosis infection. We report our experience in this field and review the various existing tests to screen for tuberculosis. Keywords: infliximab, adalimumab, tuberculosis, psoriasisFabroni CD&#39;Erme AMLotti TDove Medical PressarticleDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol 2013, Iss default, Pp 25-29 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dermatology RL1-803
spellingShingle	Dermatology RL1-803 Fabroni C D&#39;Erme AM Lotti T Biologic therapy and tuberculosis: our experience and review of literature
description	Caterina Fabroni,1 Angelo Massimiliano D’Erme,2 Torello Lotti3 1Department of Dermatology, Misericordia e Dolce Hospital, Prato, Italy; 2Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy; 3Guglielmo Marconi University, Rome, Italy Abstract: Psoriasis is an inflammatory dermatologic disease that can often involve not only the skin and mucosal surfaces but also the bones and joints. It affects approximately 3% of the world’s population, and has a chronic-relapsing course. The management of psoriasis is often difficult and, particularly in the case of moderate to severe forms, the use of systemic therapies is mandatory. The introduction of biologic drugs has greatly improved our ability to treat psoriasis. However, it is necessary to underline that antitumor necrosis factor-α treatments may reactivate latent tuberculosis infection and cause particularly disseminated or extrapulmonary disease. Physicians should carry out proper screening of patients before starting treatment with antitumor necrosis factor-α, in order to identify individuals with latent tuberculosis infection. We report our experience in this field and review the various existing tests to screen for tuberculosis. Keywords: infliximab, adalimumab, tuberculosis, psoriasis
format	article
author	Fabroni C D&#39;Erme AM Lotti T
author_facet	Fabroni C D&#39;Erme AM Lotti T
author_sort	Fabroni C
title	Biologic therapy and tuberculosis: our experience and review of literature
title_short	Biologic therapy and tuberculosis: our experience and review of literature
title_full	Biologic therapy and tuberculosis: our experience and review of literature
title_fullStr	Biologic therapy and tuberculosis: our experience and review of literature
title_full_unstemmed	Biologic therapy and tuberculosis: our experience and review of literature
title_sort	biologic therapy and tuberculosis: our experience and review of literature
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/2f4cd91aaf0b4c7fbfe63d56d3212fb3
work_keys_str_mv	AT fabronic biologictherapyandtuberculosisourexperienceandreviewofliterature AT damp39ermeam biologictherapyandtuberculosisourexperienceandreviewofliterature AT lottit biologictherapyandtuberculosisourexperienceandreviewofliterature
_version_	1718400640762249216

Biologic therapy and tuberculosis: our experience and review of literature

Ejemplares similares